# Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

> **NCT05693090** · PHASE1 · WITHDRAWN · sponsor: **Kura Oncology, Inc.**

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Tipifarnib
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT05693090
- **Lead sponsor:** Kura Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-01
- **Primary completion:** 2027-07-27
- **Final completion:** 2027-07-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was withdrawn due to a strategic business decision; no patients were enrolled.
- **Last updated:** 2023-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05693090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05693090, "Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05693090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*